227 related articles for article (PubMed ID: 2807552)
1. Purification of Shiga toxin and Shiga-like toxins I and II by receptor analog affinity chromatography with immobilized P1 glycoprotein and production of cross-reactive monoclonal antibodies.
Donohue-Rolfe A; Acheson DW; Kane AV; Keusch GT
Infect Immun; 1989 Dec; 57(12):3888-93. PubMed ID: 2807552
[TBL] [Abstract][Full Text] [Related]
2. One step high yield affinity purification of shiga-like toxin II variants and quantitation using enzyme linked immunosorbent assays.
Acheson DW; Jacewicz M; Kane AV; Donohue-Rolfe A; Keusch GT
Microb Pathog; 1993 Jan; 14(1):57-66. PubMed ID: 8321118
[TBL] [Abstract][Full Text] [Related]
3. Affinity purification and characterization of Shiga-like toxin II and production of toxin-specific monoclonal antibodies.
Downes FP; Barrett TJ; Green JH; Aloisio CH; Spika JS; Strockbine NA; Wachsmuth IK
Infect Immun; 1988 Aug; 56(8):1926-33. PubMed ID: 3294179
[TBL] [Abstract][Full Text] [Related]
4. Enzyme-linked immunosorbent assay for Shiga toxin and Shiga-like toxin II using P1 glycoprotein from hydatid cysts.
Acheson DW; Keusch GT; Lightowlers M; Donohue-Rolfe A
J Infect Dis; 1990 Jan; 161(1):134-7. PubMed ID: 2295845
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the glycolipid receptor specificities of Shiga-like toxin type II and Shiga-like toxin type II variants.
Samuel JE; Perera LP; Ward S; O'Brien AD; Ginsburg V; Krivan HC
Infect Immun; 1990 Mar; 58(3):611-8. PubMed ID: 2155181
[TBL] [Abstract][Full Text] [Related]
6. Characterization of monoclonal antibodies against Shiga-like toxin from Escherichia coli.
Strockbine NA; Marques LR; Holmes RK; O'Brien AD
Infect Immun; 1985 Dec; 50(3):695-700. PubMed ID: 3905611
[TBL] [Abstract][Full Text] [Related]
7. Isolation and characterization of monoclonal antibodies to Shiga-like toxin II of enterohemorrhagic Escherichia coli and use of the monoclonal antibodies in a colony enzyme-linked immunosorbent assay.
Perera LP; Marques LR; O'Brien AD
J Clin Microbiol; 1988 Oct; 26(10):2127-31. PubMed ID: 3053764
[TBL] [Abstract][Full Text] [Related]
8. In vivo formation of hybrid toxins comprising Shiga toxin and the Shiga-like toxins and role of the B subunit in localization and cytotoxic activity.
Weinstein DL; Jackson MP; Perera LP; Holmes RK; O'Brien AD
Infect Immun; 1989 Dec; 57(12):3743-50. PubMed ID: 2807546
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice.
Tesh VL; Burris JA; Owens JW; Gordon VM; Wadolkowski EA; O'Brien AD; Samuel JE
Infect Immun; 1993 Aug; 61(8):3392-402. PubMed ID: 8335369
[TBL] [Abstract][Full Text] [Related]
10. Identification of three amino acid residues in the B subunit of Shiga toxin and Shiga-like toxin type II that are essential for holotoxin activity.
Perera LP; Samuel JE; Holmes RK; O'Brien AD
J Bacteriol; 1991 Feb; 173(3):1151-60. PubMed ID: 1991714
[TBL] [Abstract][Full Text] [Related]
11. A monoclonal antibody to Shigella dysenteriae serotype 13 cross-reacting with Shiga toxin.
Qadri F; Azim T; Hossain A; Islam D; Mondol G; Faruque SM; Albert MJ
FEMS Microbiol Lett; 1993 Mar; 107(2-3):343-7. PubMed ID: 8472916
[TBL] [Abstract][Full Text] [Related]
12. Expression and purification of Shiga-like toxin II B subunits.
Acheson DW; De Breucker SA; Jacewicz M; Lincicome LL; Donohue-Rolfe A; Kane AV; Keusch GT
Infect Immun; 1995 Jan; 63(1):301-8. PubMed ID: 7806370
[TBL] [Abstract][Full Text] [Related]
13. Serological responses to the B subunit of Shiga-like toxin 1 and its peptide fragments indicate that the B subunit is a vaccine candidate to counter action of the toxin.
Boyd B; Richardson S; Gariepy J
Infect Immun; 1991 Mar; 59(3):750-7. PubMed ID: 1705242
[TBL] [Abstract][Full Text] [Related]
14. Purification and some properties of a Vero toxin from a human strain of Escherichia coli that is immunologically related to Shiga-like toxin II (VT2).
Oku Y; Yutsudo T; Hirayama T; O'Brien AD; Takeda Y
Microb Pathog; 1989 Feb; 6(2):113-22. PubMed ID: 2654533
[TBL] [Abstract][Full Text] [Related]
15. Neutralizing antibodies against Shiga-like toxins from Escherichia coli in colostra and sera of cattle.
Pirro F; Wieler LH; Failing K; Bauerfeind R; Baljer G
Vet Microbiol; 1995 Feb; 43(2-3):131-41. PubMed ID: 7740752
[TBL] [Abstract][Full Text] [Related]
16. Development and evaluation of enzyme-linked immunosorbent assays for detection of shiga-like toxin I and shiga-like toxin II.
Downes FP; Green JH; Greene K; Strockbine N; Wells JG; Wachsmuth IK
J Clin Microbiol; 1989 Jun; 27(6):1292-7. PubMed ID: 2666439
[TBL] [Abstract][Full Text] [Related]
17. Functional analysis of the Shiga toxin and Shiga-like toxin type II variant binding subunits by using site-directed mutagenesis.
Jackson MP; Wadolkowski EA; Weinstein DL; Holmes RK; O'Brien AD
J Bacteriol; 1990 Feb; 172(2):653-8. PubMed ID: 2404947
[TBL] [Abstract][Full Text] [Related]
18. The specific activities of Shiga-like toxin type II (SLT-II) and SLT-II-related toxins of enterohemorrhagic Escherichia coli differ when measured by Vero cell cytotoxicity but not by mouse lethality.
Lindgren SW; Samuel JE; Schmitt CK; O'Brien AD
Infect Immun; 1994 Feb; 62(2):623-31. PubMed ID: 8300218
[TBL] [Abstract][Full Text] [Related]
19. Cloning and sequencing of a Shiga-like toxin type II variant from Escherichia coli strain responsible for edema disease of swine.
Weinstein DL; Jackson MP; Samuel JE; Holmes RK; O'Brien AD
J Bacteriol; 1988 Sep; 170(9):4223-30. PubMed ID: 3045088
[TBL] [Abstract][Full Text] [Related]
20. Production and characterisation of monoclonal antibodies to Verotoxins 1 and 2 from Escherichia coli of serotype O 157:H7.
Padhye VV; Zhao T; Doyle MP
J Med Microbiol; 1989 Nov; 30(3):219-26. PubMed ID: 2479749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
